Licensing Opportunities

The Anthrocell® Expression System (ACX™) is available for licensing for both commercial and research applications, with significant advantages in both contexts.

For research applications, ACX is an attractive alternative to HEK, with high transfection rates enabling a stable clone within 90 days and the ability to save on the migration to CHO.

For commercial applications, the fully human PTMs provides by ACX offers the prospect of superior clinical outcomes and higher prospects of clinical trial success.